Wils J A
Laurentius Hospital, Roermond, The Netherlands.
Anticancer Res. 1987 Jul-Aug;7(4B):755-9.
A review of the current status of chemotherapy in advanced gastric cancer is presented. Results of recent randomized trials have questioned the merits of the most commonly used chemotherapy protocols such as combinations of 5-fluorouracil (5-FU) and doxorubicin with mitomycin C or a nitrosourea (FAM, MeFA, FAB) over 5-FU alone. Results of new ("second generation") protocols and the impact of these results on future trials in an adjuvant setting and in advanced disease are discussed. For the time being no "standard" chemotherapy can be advocated and patients should preferably be treated in clinical trials.
本文综述了晚期胃癌化疗的现状。近期随机试验的结果对最常用的化疗方案（如5-氟尿嘧啶（5-FU）与阿霉素联合丝裂霉素C或亚硝基脲（FAM、MeFA、FAB））相对于单独使用5-FU的优势提出了质疑。讨论了新的（“第二代”）方案的结果以及这些结果对辅助治疗和晚期疾病未来试验的影响。目前无法推荐任何“标准”化疗方案，患者最好参加临床试验进行治疗。
